The series on “Frontiers in Bronchiectasis Management: Translational Science and Practice” is dited by Prof. James D Chalmers and Prof. Weijie Guan.
Frontiers in bronchiectasis management: Translational science and practice will cover the status quo of bronchiectasis registry, clinical phenotypes and endotypes, pharmacological (e.g. antibiotics) and non-pharmacological (e.g. airway clearance) treatment of bronchiectasis. Moreover, bronchiectasis management in children will also be the important topic for this special series. We believe this special series will provide an excellent insight of the molecular mechanisms, diagnosis and integrated clinical management of bronchiectasis. Besides, free submissions are welcome to this series.
Prof. James D Chalmers
Professor James D. Chalmers is the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland and an honorary consultant physician at Ninewells Hospital. His clinical and research interests are in difficult respiratory infections, particularly bronchiectasis, COPD and COVID-19. He runs a translational research programme using mechanistic, translational and clinical approaches to develop new treatments for inflammatory lung disease. He is chair of the Science and Research Committee of the British Thoracic Society and is chair of the European Bronchiectasis Registry (EMBARC). He was appointed deputy chief editor of the ERJ in 2018 and was appointed Chief Editor in 2022. He has won a number of awards for research and teaching including the John Munro Medal for Teaching from the Royal College of Physicians of Edinbrgh (2014), the Romain Pauwels Award from the European Respiratory Society (2017), The Patrick Neil Medal from the Royal Society of Edinburgh (2017) and the Cournand Lecture Award from the European Respiratory Society (2021).
Prof. Weijie Guan
Prof. Guan is the Principal Investigator of the Department of Respiratory and Critical Care Medicine at the First Affiliated Hospital of Guangzhou Medical University, Deputy Director of National Clinical Medical Research Center for Respiratory Diseases, Director Assistant of Guangzhou Institute for Respiratory Health. He also serves as the Deputy Director of Bronchiectasis-China Alliance. His research field is focusing on chronic airway inflammatory diseases. He has been awarded as the National Science Foundation - Outstanding Youth fund, Elsevier “Chinese highly cited scholar” (2020-2023), Elsevier World's Top 2% scientist (Annual + career achievement) (2020-2023), and the Peer Review award of European Respiratory Journal (2019). Apart from acting as the Associate Editor for ERJ Open Research, the Editorial Board Member for European Respiratory Journal and Journal of Thoracic Disease, he also serves as an active peer reviewer in a wide range of medical journals including: The Lancet, Lancet Respiratory Medicine, Lancet Planetary Health, AJRCCM, etc.
Series outline:
- Addressing treatable traits in bronchiectasis through non-pharmacological therapies: a narrative review
- DPP-1 inhibitors and neutrophilic inflammation in bronchiectasis: a narrative review
- Phenotypes and endotypes in bronchiectasis: a narrative review of progress toward precision medicine
- Bronchodilators and inhaled corticosteroids use in major global bronchiectasis registries
- Making real progress in the world of bronchiectasis
- Pediatric Bronchiectasis - the importance of early diagnosis of children across the chronic wet cough spectrum
- Use of long-term inhaled antibiotics and macrolides: insights from the four global bronchiectasis registries
- What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?—data from the RIBRON registry
- Allergic bronchopulmonary aspergillosis and aspergillus disease in bronchiectasis
Welcome your support to the focused series!
Disclosure:
The series “Frontiers in Bronchiectasis Management: Translational Science and Practice” was commissioned by the editorial office, Journal of Thoracic Disease without any sponsorship or funding. Prof. James D Chalmers and Prof. Weijie Guan are serving as the unpaid Guest Editors for the series.